Pediatrix Medical Group/$MD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pediatrix Medical Group

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Ticker

$MD
Sector

Primary listing

NYSE

Employees

4,120

MD Metrics

BasicAdvanced
$1.5B
13.52
$1.29
1.21
-

What the Analysts think about MD

Analyst ratings (Buy, Hold, Sell) for Pediatrix Medical Group stock.

Bulls say / Bears say

Pediatrix reported non-GAAP EPS of $0.53 in Q2 2025, topping the analyst consensus of $0.42 by 25.9%, and raised its full-year 2025 adjusted EBITDA guidance to $245–255 million from $220–240 million, reflecting strong execution and management confidence (Investing.com).
The company cut net debt from $515 million on September 30, 2024, to $386 million by year-end 2024, achieving net leverage of roughly 1.7 times while generating $135 million of operating cash flow in Q4 2024, improving balance sheet strength (GuruFocus).
Pediatrix repurchased $1.8 million of its own shares in H1 2025 and has $1.1 million remaining capacity under its $500 million buyback authorization, highlighting commitment to returning capital to shareholders (Nasdaq).
GAAP revenue for Q2 2025 declined by 7.0% year-over-year to $468.8 million, mainly due to practice sales, highlighting potential challenges in sustaining top-line growth through portfolio restructuring (Investing.com).
As of June 30, 2025, Pediatrix had total debt of $607.5 million, barely reduced from $615 million at year-end 2024, leaving the company vulnerable to interest-rate risk and liquidity pressures in a high-rate environment (Zacks).
Operating cash flow in H1 2025 was only $19.7 million, showing relatively weak cash generation compared to its debt load and capital spending needs, which could strain liquidity if not addressed (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MD Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MD Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs